

Title (en)

GENETICALLY TRANSFECTED HUMAN DENDRITIC CELLS, THEIR PRODUCTION AND USE, PREFERABLY AS VACCINES

Title (de)

GENTRANSFIZIERTE HUMANE DENDRITISCHE ZELLEN, IHRE HERSTELLUNG UND IHRE VERWENDUNG, BEVORZUGT ALS VAKZINE

Title (fr)

CELLULES DENDRITIQUES HUMAINES GENETIQUEMENT TRANSFECTEES, LEUR PRODUCTION ET LEUR UTILISATION, DE PREFERENCE COMME VACCINS

Publication

**EP 0906444 A1 19990407 (DE)**

Application

**EP 97922844 A 19970414**

Priority

- DE 9700772 W 19970414
- DE 19617837 A 19960419
- DE 19617846 A 19960419

Abstract (en)

[origin: WO9740182A1] Genetically transfected human dendritic cells are disclosed, as well as their production and use, preferably as vaccines. The invention has applications in the pharmaceutical industry and in medicine. The dendritic cells are produced by transfection with a foreign gene by means of liposomes, preferably by means of lipofectin, a liposome preparation. The disclosed vaccine consists of human, autologous dendritic cells transfected with a partial sequence of the human mucine-MUC1 gene which contains several tandem repeat nucleotide sequences of MUC1. By using a glycosylation inhibitor, tumour-associated epitopes are created in these cells, preferably at their surface.

IPC 1-7

**C12N 15/88**; **C12N 15/12**; **C12N 5/10**; **A61K 48/00**

IPC 8 full level

**C07K 14/47** (2006.01); **C12N 15/12** (2006.01); **A61K 39/00** (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP US)

**A61K 39/46** (2023.05 - EP US); **A61K 39/4615** (2023.05 - EP US); **A61K 39/4622** (2023.05 - EP US); **A61K 39/46447** (2023.05 - EP US); **A61K 2239/46** (2023.05 - US); **C07K 14/4727** (2013.01 - EP); **A61K 39/00** (2013.01 - EP US); **A61K 48/00** (2013.01 - EP); **A61K 2239/46** (2023.05 - EP)

Designated contracting state (EPC)

AT BE CH DE DK FI FR GB IT LI NL SE

DOCDB simple family (publication)

**WO 9740182 A1 19971030**; EP 0906444 A1 19990407

DOCDB simple family (application)

**DE 9700772 W 19970414**; EP 97922844 A 19970414